Kim Hyo Song, Lee Jeeyun, Yi Seong Yoon, Jun Hyun Jung, Choi Yoon-La, Ahn Geung Hwan, Seo Sung Wook, Lim Do Hoon, Ahn Yong Chan, Park Joon Oh, Kim Sung Joo
Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
BMC Cancer. 2009 Jun 26;9:205. doi: 10.1186/1471-2407-9-205.
Prognosis and optimal treatment strategies of liposarcoma have not been fully defined. The purpose of this study is to define the distinctive clinical features of liposarcomas by assessing prognostic factors.
Between January 1995 and May 2008, 94 liposarcoma patients who underwent surgical resection with curative intent were reviewed.
Fifty patients (53.2%) presented with well differentiated, 22 (23.4%) myxoid, 15 (16.0%) dedifferentiated, 5 (5.3%) round cell, and 2 (2.1%) pleomorphic histology. With the median 14 cm sized of tumor burden, about half of the cases were located in the retroperitoneum (46.8%). Seventy two (76.6%) patients remained alive with 78.1%, and 67.5% of the 5- and 10-year overall survival (OS) rates, respectively. Low grade liposarcoma (well differentiated and myxoid) had a significantly prolonged OS and disease free survival (DFS) with adjuvant radiotherapy when compared with those without adjuvant radiotherapy (5-year OS, 100% vs 66.3%, P = 0.03; 1-year DFS, 92.9% vs 50.0%, respectively, P = 0.04). Independent prognostic factors for OS were histologic variant (P = 0.001; HR, 5.1; 95% CI, 2.0 - 12.9), and margin status (P = 0.005; HR, 4.1; 95% CI, 1.6-10.5). We identified three different risk groups: group 1 (n = 66), no adverse factors; group 2, one or two adverse factors (n = 28). The 5-year OS rate for group 1, and 2 were 91.9%, 45.5%, respectively.
The histologic subtype, and margin status were independently associated with OS, and adjuvant radiotherapy seems to confer survival benefit in low grade tumors. Our prognostic model for primary liposarcoma demonstrated distinct three groups of patients with good prognostic discrimination.
脂肪肉瘤的预后及最佳治疗策略尚未完全明确。本研究旨在通过评估预后因素来明确脂肪肉瘤的独特临床特征。
回顾1995年1月至2008年5月间94例行根治性手术切除的脂肪肉瘤患者。
50例(53.2%)为高分化,22例(23.4%)为黏液样,15例(16.0%)为去分化,5例(5.3%)为圆形细胞,2例(2.1%)为多形性组织学类型。肿瘤负荷中位数大小为14厘米,约半数病例位于腹膜后(46.8%)。72例(76.6%)患者存活,5年和10年总生存率(OS)分别为78.1%和67.5%。与未接受辅助放疗的患者相比,低级别脂肪肉瘤(高分化和黏液样)接受辅助放疗后OS和无病生存期(DFS)显著延长(5年OS,100%对66.3%,P = 0.03;1年DFS分别为92.9%对50.0%,P = 0.04)。OS的独立预后因素为组织学亚型(P = 0.001;HR,5.1;95%CI,2.0 - 12.9)和切缘状态(P = 0.005;HR,4.1;95%CI,1.6 - 10.5)。我们确定了三个不同风险组:第1组(n = 66),无不良因素;第2组,有一或两个不良因素(n = 28)。第1组和第2组的5年OS率分别为91.9%、45.5%。
组织学亚型和切缘状态与OS独立相关,辅助放疗似乎能使低级别肿瘤患者生存获益。我们的原发性脂肪肉瘤预后模型显示出三组不同患者,具有良好的预后区分度。